Pazopanib: Clinical development of a potent anti-angiogenic drug

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 3, 2011, Pages 163-171

  Schutz, Fabio A B ^a   Choueiri, Toni K ^a   Sternberg, Cora N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Pazopanib; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; DEPIGMENTATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; THYROID CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PYRIMIDINES; SULFONAMIDES;

EID: 79952189697     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.02.012     Document Type: Review

References (60)

1. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(June (12)):1788-1795.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175(March (3)):409-416.
3. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(August (3)):353-364.
4. Berse B., Brown L.F., Van de Water L., Dvorak H.F., Senger D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992, 3(February (2)):211-220.
5. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7(September (9)):870-879.
6. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004, 15(August (4)):275-286.
7. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(October (9544)):1329-1338.
8. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(July (4)):378-390.
9. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(January (2)):115-124.
10. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(January (2)):125-134.
11. Harris P.A., Boloor A., Cheung M., et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008, 51(August (15)):4632-4640.
12. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(July (7)):2012-2021.
13. Hurwitz H.I., Dowlati A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15(June (12)):4220-4227.
14. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100(May (9)):1385-1392.
15. Yau C.C., Chen P.J., Curtis C.M., et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(15s). (suppl; abstr 3561).
16. Brady J., Middleton M., Midgley R.S., et al. A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer. J Clin Oncol 2009, 27(15s). (suppl; abstr 4133).
17. Frentzas S.N., Groves M.D., Barriuso J., et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a phase I/II study. J Clin Oncol 2009, 27(15s). (suppl; abstr 2040).
18. United States National Institutes of Health. Accessed on October 11, 2009. http://www.clinicaltrials.gov/ct2/search.
19. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7(May (1)):85-90.
20. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180(September (3)):860-865. discussion 5-6.
21. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48(1):9-17.
22. Wu S., Chen J.J., Kudelka A., Lu J., Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008 Feb, 9(2):117-123.
23. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10(October (10)):967-974.
24. Sher A.F., Chu D., Wu S. Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: a meta-analysis. J Clin Oncol 2009, 27(15s). (suppl; abstr 9584).
25. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10(June (6)):559-568.
26. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99(August (16)):1232-1239.
27. Nalluri S.R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300(November (19)):2277-2285.
28. Chu D., Lacouture M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009, 7(January (1)):11-19.
29. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49(February (2)):186-193.
30. Hutson T.E., Davis I.D., Machiels J.H., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26(15s). (suppl; abstr 5046).
31. Sternberg C.N., Szczylik C., Lee E., et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(15s). (suppl; abstr 5021).
32. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(March (5)):1706-1716.
33. Slamon D., Gomez H.L., Kabbinavar F.F., et al. Randomized study of pazopanib+lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008, 26(15s). (suppl; abstr 1016).
34. Taylor S.K., Chia S., Dent S., et al. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009, 27(15s). (suppl; abstr 1133).
35. Chang S., Parker S.L., Pham T., Buzdar A.U., Hursting S.D. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998, 82(June (12)):2366-2372.
36. Hance K.W., Anderson W.F., Devesa S.S., Young H.A., Levine P.H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005, 97(July (13)):966-975.
37. Kleer C.G., van Golen K.L., Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000, 2(6):423-429.
38. Johnston S., Trudeau M., Kaufman B., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26(March (7)):1066-1072.
39. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24(February (5)):769-777.
40. Lennard C.M., Patel A., Wilson J., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001, 129(May (5)):552-558.
41. Bible K.C., Smallridge R.C., Maples W.J., et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol 2009, 27(15s). (suppl; abstr 3521).
42. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26(October (29)):4708-4713.
43. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26(October (29)):4714-4719.
44. Cohen E.E., Needles B.M., Cullen K.J., et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008, 26(15s). (suppl; abstr 6025).
45. Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001, 84(June (12)):1610-1615.
46. Chao C., Al-Saleem T., Brooks J.J., Rogatko A., Kraybill W.G., Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001, 8(April (3)):260-267.
47. Pakos E.E., Goussia A.C., Tsekeris P.G., Papachristou D.J., Stefanou D., Agnantis N.J. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005, 25(September-October (5)):3591-3596.
48. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27(July (19)):3126-3132.
49. Keohan M.L., Morgan J.A., D'Adamo D.R., et al. Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial. J Clin Oncol 2008, 26(15s). (suppl; abstr 10533).
50. Maki R.G., Keohan M.L., Undevia S.D., et al. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. J Clin Oncol 2008, 26(15s). (suppl; abstr 10531).
51. Hammes L.S., Tekmal R.R., Naud P., et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008, 110(September (3)):445-451.
52. Gaffney D.K., Haslam D., Tsodikov A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56(July (4)):922-928.
53. Monk B., Mas L., Zarba J.J., et al. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol 2009, 27(15s). (suppl; abstr 5520).
54. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(June (6)):669-676.
55. Hawkins R.E., Hong S.J., Ulys A., Rolski J., Hong B., Sternberg C.N. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(15s). (suppl; abstr 5110).
56. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(August (22)):3584-3590.
57. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(November (33)):5422-5428.
58. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(December (9605)):2103-2111.
59. Bayer. NEXAVAR Prescribing Information. (accessed June 2, 2009). http://www.univgraph.com/bayer/inserts/nexavar.pdf.
60. Pfizer. SUTENT Prescribing Information. (accessed Jun 2, 2009). https://www.pfizeroncology.com/sites/pop/PDFs/uspi_sutent.pdf.